Q BioMed Inc., a New York-based biotechnology acceleration company, announced today the launch of www.PainFreeCancer.com. This website is designed to provide a resource for patients, doctors and caregivers dealing with the severe pain associated with late stage cancer metastases to the bone.

U.S. Food and Drug Administration approved Generic Strontium Chloride Sr89 Injection, USP (Strontium-89) is a NON-OPIOID pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. In the body, Strontium-89 acts similar to calcium and is preferentially taken up in osteoblastic tissue selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone. Up to 80% of patients report pain relief lasting months.

Strontium Chloride Sr89 Injection, USP can be used in combination with other therapeutic drugs. Clinical studies have demonstrated that the combination of alternating weekly chemohormonal therapies with Strontium-89 demonstrated a prolonged progression-free and overall survival in patients.

Strontium Chloride Sr89 Injection, USP Usage and Indications:

Following intravenous injection, soluble strontium compounds behave like their calcium analogs, clearing rapidly from the blood and selectively localizing in bone mineral. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis, thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone. Strontium-89 is retained in metastatic bone lesions much longer than in normal bone, where turnover is about 14 days. In patients with extensive skeletal metastases, well over half of the injected dose is retained in the bones. Strontium-89 is a pure beta emitter and Strontium-89 selectively irradiates sites of primary and metastatic bone involvement with minimal irradiation of soft tissues distant from the bone lesions. (The maximum range in tissue is 8 mm; maximum energy is 1.463 MeV.) Clinical trials have examined relief of pain in cancer patients who have received therapy for bone metastases (external radiation to indexed sites) but in whom persistent pain recurred.

INDICATIONS AND USAGE: Strontium-89 Chloride Injection is indicated for the relief of bone pain in patients with painful skeletal metastases. The presence of bone metastases should be confirmed prior to therapy.

For more information, please visit www.PainFreeCancer.com